ENSC - Cash Flow Statement - Ensysce Biosciences, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017
OPERATING CASH FLOW
Net Income	(8.0)	(10.6)	(24.2)	(29.1)	(0.2)	0.4	(1.3)	31.2 K
Depreciation & Amortization	0	0	0	151	201	201	0	0
Deferred Income Tax	0	0	0	14.6	(2.4)	1.76 K	1.76 K	0
Stock Based Compensation	110 723.0	0.9	1.1	0.1	0.2	6.0	0	0
Other Operating Activities	(7 613 414.2)	85.8 K	(0.2)	7.5	1.0	8.2	(0.3)	(0.2)
Change in Working Capital	(0.9)	(0.9)	5.5	(1.3)	0.2	2.5	0.3	(0.1)
Cash From Operations	(7 502 700.0)	(10.8)	(17.9)	(8.2)	(1.2)	11.0	(1.2)	(0.3)
INVESTING CASH FLOW
Capital Expenditures	0	2	0	0	0	0	0	0
Other Items	0	2	4.5 K	0	183.4	(0.6)	0.8	(200.0)
Cash From Investing Activities	0	0	4.5 K	0	183.4	(0.6)	0.8	(200.0)
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	(11.6)	0	0
Total Debt Repaid	(0.5)	0.6	6.1	13.9	1.1	0.4	0	0
Dividends Paid	(290.0)	0	(0.9)	(803 140.0)	0	0	0	0
Other Financing Activities	9 881 461.8	(0.9)	3.6	(0.2)	20	0.2	0	0
Cash From Financing Activities	9 881 173.0	8.8	8.8	20.3	1.1	(11.0)	32 K	202.3
CHANGE IN CASH
Net Change In Cash	2 378 473.0	(2.0)	(9.1)	12.1	(0.1)	(0.6)	(0.4)	2.1
FREE CASH FLOW
Free Cash Flow	(7 502 700.0)	(10.8)	(17.9)	(8.2)	(1.2)	11.0	(1.2)	(0.3)

Free